Pfizer granted Mylan exclusive rights in the U.S., EU, Canada, Australia and New Zealand to generic fluticasone propionate/salmeterol incorporating Pfizer's inhalational delivery system

Pfizer Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Mylan N.V.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced